dicinal Products (CPMP) of the European Medicines Agency (EMA) and the Monograph in the European Pharmacopoeia govern writing and regular updating of these guidelines.
The following issues are regulated: how plasma is obtained, the screening of donated plasma, viral safety issues, methods of biological and pharmacological characterization and the testing of end products for clinical efficacy. The national authorities are responsible for authorizing the preparations, in that they carry out testing and define from which countries blood and plasma may be obtained. The national authorities are also responsible for the regular inspection of the manufacturing process and for virological testing, as well as for the approval of any changes to the manufacturing process.
The manufacturing pathway for immunoglobulin preparations starts with the identification of suitable donors. These donors must be healthy and must not have any signs of infections or chronic diseases. All plasma donations must be free of HBs antigen and anti-HCV antibodies as well as negative for HIV-1 and HIV-2 antibodies. All plasma donations are also subject to a "lookback" procedure with a holding period of at least 60 days. Any seroconversion of a donor occurring during this time can thus be detected and all stored plasma from the donor quarantined will be destroyed. Nucleic acid amplification technology (polymerase chain reaction; PCR) is used to screen the plasma from individual donors as well as the resulting plasma pool for the presence of HCV RNA, HBV DNA, HIV RNA, HAV RNA and Parvovirus B19 DNA. In the event of a reactive finding, the relevant plasma donations will be rejected/the plasma pool destroyed. Besides immunoglobulin concentration steps, plasma processing includes several independent process steps for virus inactivation/removal. A range of both enveloped and non-enveloped model viruses are used to spike the test preparations in order to quantify and validate the log reduction in virus of each individual step in the process. In addition to the antiviral properties of the manufacturing processes there are a number of dedicated steps for virus inactivation/removal which vary between manufacturers. For each batch of immunoglobulin manufactured, a certificate is produced which provides information on the main biological and pharmacological properties, the degree of purity and the antibody spectrum.
Besides viral safety, the clinical efficacy of the immunoglobulin preparations is also tested during this manufacturing process. Testing of functional integrity, determination of neutralizing antibodies and monitoring of immunomodulatory inflammatory properties is carried out on the basis of established test methods. Studies are also required in patients with primary antibody deficiencies. The successful treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) is considered as evidence of the immunomodulatory activity of a preparation. and secondary immune deficiency. Side effects of the current generation of products are generally considered to be minimal, however when using high dose therapy physicians should be aware of uncommon serious adverse events such as thromboembolic complications. In dermatology, IVIg is used mainly in the treatment of autoimmune diseases and toxic epidermal necrolysis. Although the list of diseases treated is long, it is generally based on small series or isolated case reports in uncontrolled studies. This is partly because the number of patients with these rare conditions is too small for large studies and it is usually difficult to compare the patients because of the very heterogeneous clinical courses and because of the concomitant medication used. As a result of the high costs of treatment, use of the preparations has to be highly selective, which makes it even more difficult to find large case series.
The aim of the current guidelines was to answer the following questions for each clinical condition:
1.
Diseases for which IVIg is indicated? The use of IVIg therapy is considered to be an adjuvant treatment with continuation of immunosuppressive therapy with corticosteroids and possibly also other immunosuppressive agents (Dalakas et al, 1995) . IVIg monotherapy has generally been less effective. From the immunological perspective, sufficient bone marrow function needs to be available given the concomitant immunosuppressive therapy. Therefore, treatment onset should not be delayed for too long.
Initial duration of treatment:
Initial treatment should be carried out over a period of 6 months in order to determine the efficacy of treatment with IVIg. If therapeutic efficacy has not been achieved after 6 treatment cycles, the IVIg treatment should be discontinued. After 18 treatment cycles, a washout period should be attempted. It is possible to increase the interval between infusions to a maximum of 6 weeks beforehand. In the event of recurrences, treatment can be resumed at any time. This recommendation needs to be adapted to the course of disease for each individual patient (some patients need longer treatment).
Interval between infusions:
Initially, adjuvant IVIg therapy should be administered every 4 weeks. If a good clinical response is achieved, the interval can be increased gradually to a maximum of 6 weeks. Longer intervals between infusions are not recommended.
IVIg dosing:
The bulk of evidence with respect to the use of IVIg in dermatological autoimmune diseases has been obtained with a dose of 2 g per kg body weight per treatment cycle. Because there is no clear evidence of efficacy with lower doses, adherence to the aforementioned dose recommendations is advised in these serious diseases.
Although there has been one report on the successful use of subcutaneously applied Ig in polymyositis and dermatomyositis in seven patients, this study awaits confirmation in larger patient cohorts (Danieli et al, 2011) . Therefore s.c. Ig cannot generally be recommended in dermatomyositis.
Period of IVIg administration:
Administration of the immunoglobulin should be spread over 2-5 consecutive days. Tolerability is generally better with greater dose fractionation. In patients with cardiac or renal impairment, immunoglobulin preparations should be administered over a longer period of time. If the treatment is well tolerated at the beginning, it can generally also be carried out on an outpatient basis.
Evaluation of therapeutic efficacy:
The clinical picture is the most important parameter for evaluating the efficacy of treatment in dermatomyositis, with evaluation of muscle strength playing the most important role. Autoantibody titers, on the other hand, do not reflect the response to treatment. In general, creatine kinase and muscle aldolase levels also return rapidly to normal under immunosuppressive therapy. This prohibits their use as indicators of efficacy. MRI or ultrasonography of the proximal muscle groups is important for the initial diagnosis as is specific muscle biopsy, but are unsuitable for close monitoring. The criteria for evaluating the clinical response is therefore normalization of muscle strength with gradual tapering of the steroid dose, fading of erythema and gradual resolution of other parameters such as Gottron's papules while on IVIg therapy. It is our experience that a response can be detected from the second treatment cycle on, mainly by the patient (especially on the basis of the improvement in muscle strength) but also by the treating physician. Nevertheless, tapering the concomitant medication too rapidly should be avoided. Between 3 and 4 treatment cycles are often required before a significant improvement in symptoms is seen and in severely affected patients, extension of treatment intervals needs to be done with care.
Long-term IVIg therapy:
In rare cases, long-term therapy may be necessary in patients with severe dermatomyositis and a prolonged course, although therapy-cessation periods should be attempted to allow the effects of the IVIg therapy on the course of the disease to be assessed.
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Autoimmune blistering diseases:
The autoimmune blistering diseases are autoantibody-mediated disorders, the autoantigens of which are largely known and have been molecularly characterized. Autoimmune blistering diseases are generally treated by dermatologists only and are therefore of great importance for our speciality. The following recommendations were drawn up for the use of IVIg in these diseases: 
Timing of treatment:
On the basis of the scientific evidence available, the use of IVIg cannot be recommended as a first-line treatment. However, contraindications to standard immunosuppressive therapy (e.g., aseptic bone necrosis, poorly controlled diabetes or advanced osteoporosis and cataracts) may justify the use of IVIg as a first-line treatment in isolated cases. Consequently, immunoglobulins should primarily be used as a second-line treatment following sufficient combination therapy with steroids (e.g. prednisolone 1-2 mg per kg body weight per day) and another immunosuppressive agent (e.g. azathioprin). Here again, IVIg is an adjuvant therapy, which must be administered while continuing the conventional immunosuppressive therapy. IVIg may also be considered in patients treated with rituximab in whom sufficient disease control was not attained. This also means that immunoglobulin use should not be delayed for too long because adjuvant treatment is useful only with concomitant immunosuppressive therapy and this requires adequate bone marrow function. Monotherapy with immunoglobulin is generally not recommended.
Initial duration of treatment:
Treatment should be administered initially for a period of between 3-6 months in order to assess the efficacy of the IVIg in each individual case. Some patients do not show a definitive sustained response until they have undergone up to 6 cycles of treatment. If a therapeutic response cannot be documented after 6 cycles of therapy IVIg treatment should be discontinued. This recommendation needs to be adapted to the course of disease for each individual patient (some patients may need longer treatment).
Interval between infusions:
Adjuvant therapy with IVIg should be administered every 4 weeks initially. If the clinical response is good, the interval between infusions can be increased gradually to a maximum of 6 weeks. Longer intervals are not recommended.
Dosing:
As already mentioned above, most studies have used a total dose of 2 g per kg body weight by intravenous infusion. Because only insufficient data are available at present for higher or lower doses, this dosage should be considered as the standard recommendation at present. Regular washout periods should be attempted.
Vasculitic syndromes:
Vasculitic syndromes are systemic inflammatory conditions which affect the blood vessels of one or more organ system. A distinction is made between primary and secondary systemic vasculitic syndromes. Because the skin is often involved as an indicator organ and the conditions often prove highly refractory to treatment, immunoglobulin is often considered as a therapeutic alternative. The following recommendations can be made on the basis of our current state of knowledge: 
Initial duration of treatment:
As with the aforementioned indications, a treatment period of 3-6 months is useful initially in order to obtain a clear idea of the response to treatment.
Interval between infusions:
As described above, treatment should be administered at 4-week intervals initially. If the clinical response is good, the intervals between infusions can be extended gradually to a maximum of 6 weeks. A clear benefit of longer treatment intervals has not been documented.
Dosing:
The recommended dose for the treatment of Kawasaki syndrome in children is again 1.6-2 g per kg body weight per treatment cycle (as bolus infusion or divided into single infusions given over 2-5 days 2) in addition to the recommended administration of acetylsalicylic acid with an initial dose of 50 mg/kg body weight per day. On the basis of this, all case series of patients with systemic vasculitic syndromes have so far been treated with a total dose of 2 g per kg body weight.
Duration of treatment:
Treatment should be administered over a period of 2-5 days, with a longer duration of treatment being associated with fewer side effects. In the case of systemic vasculitis with renal involvement in particular, the infusion rate should be reduced or possibly a reduced dose should be used (e.g., a total of 1 g per kg body weight).
Evaluation of treatment efficacy:
The clinical response should be the main criterion used for evaluating therapeutic efficacy. Because organ involvement is rather heterogeneous, only general recommendations can be expressed here. The pattern of CRP and organspecific laboratory tests, can be used as indicators of response. As an example, in Wegener's granulomatosis, the c-ANCA titre and level of the proteinase 3 (PR3) ELISA can be used as additional indicators.
Long-term therapy:
Long-term therapy with IVIg is recommended only in exceptional cases.
Lupus erythematosus, and other collagen vascular diseases:
Almost all autoimmune connective tissue diseases have already been treated experimentally with IVIg in small series. The best data exist for systemic lupus erythematosus. The following recommendations are proposed: 
Timing of treatment:
The use of IVIg is generally not a first-line treatment option. Previous combination treatment with steroids and another immunosuppressive associated with a poor response or severe complications is considered an indication for the use of IVIg. Again, however, the use of IVIg should not be delayed for too long in conditions such as lupus nephritis to avoid tissue damage. Here too, treatment should be given in combination with adequate immunosuppressive therapy.
Initial duration of treatment:
As with the aforementioned conditions, application of IVIg is initially recommended over a period of 6 months. If there has been no response to treatment after this time, treatment should be discontinued.
Interval between infusions:
The initial interval between infusions should again be 4
weeks. The interval between the individual bolus infusions can then be increased gradually to 6 weeks.
Dosing:
Again, the only experience available in the conditions listed above is with the standard dose of 2 g per kg body weight. This should be adopted as the standard recommendation.
Treatment period:
Treatment should be administered over a period of 2-5 days. In the case of severe organ involvement such as kidney or heart involvement in particular, the treatment period should be increased to 5 days.
Evaluation of treatment efficacy:
The focus is again on the clinical evaluation of treatment efficacy. Because this is a very heterogeneous group of diseases, it is only possible to express the general recommendation that improvement in primary organ involvement (e.g.
protein excretion in the urine) should be used as an indicator of response. In isolated cases, the pattern of disease-specific autoantibodies such as double-strand DNA antibodies can be used as an indicator of response in systemic lupus erythematosus.
Long-term therapy:
Long-term therapy can be recommended only in exceptional cases.
Scleromyxedema:
Scleromyxedema is a severe multi-organ condition characterized by fibroblast proliferation and mucin deposition in skin and internal organs associated with monoclonal gammopathy in the majority of cases. Thickening and fibrosis of skin often cause a debilitating situation and internal organ involvement can put the patient's life at risk (Kukova et 
Timing of treatment:
IVIg should be considered treatment of choice in refractory cases of scleromyxedema with either fast deterioration of skin symptoms, the dermato-neuro syndrome or life-threatening involvement of internal organs. In milder cases, initial treatment with immunosuppressive regimens should be undertaken. Failure to respond to such treatment or contraindications to such treatments justify initiation of treatment with IVIg. In scleromyxedema no additional treatments are needed besides IVIg.
Initial duration of treatment:
As with the other conditions, the use of IVIg is initially recommended over a period of 6 months. If there has been no response to treatment after this time, treatment should be discontinued.
Interval between infusions:
The initial interval between infusions should be 4 weeks. The interval between the individual bolus infusions can then be increased gradually to 6 weeks.
Any additional increase in the interval is not recommended.
Dosing:
Most experience in scleromyxedema exists with the standard dose of 2 g per kg body weight. This should be adopted as the standard recommendation.
Treatment period:
Evaluation of treatment efficacy:
The focus lies on the clinical evaluation of treatment efficacy. As skin involvement is present in nearly all cases and responds very well to treatment with IVIg, it should be used as an indicator of response. In isolated cases, clinical response to CNS or internal organ involvement can be used as additional indicator of response in scleromyxedema.
Long-term therapy:
It has been documented in several cases that after discontinuation of
IVIg there are relapses (Bidier et al, 2012; Rongioletti et al, 2013) . If a relapse is severe and life-threatening, long-term therapy can be recommended in exceptional cases.
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Toxic epidermal necrolysis:
Toxic epidermal necrolysis represents a life-threatening side effect of drugs (Pereira et al, 2007 ). The condition is associated with Fas (CD95) and granulysin-mediated apoptosis, as well as annexin A1-mediated necroptosis of epidermal keratinocytes (Harr et al, 2010 ).
Therefore it is assumed that antibodies interfering with these apoptotic pathways (and contained in IVIg preparations) might be beneficial in this disease (Viard et al, 1998) . 
Initial duration of treatment:
Only one cycle of treatment is usually required in this condition, administered over a period of 3-5 days.
Dosing:
The dose recommendation in toxic epidermal necrolysis differs from that in autoimmune diseases. A total dose of at least 3 g per kg body weight is generally recommended.
Fractionated administration (over 3-5 days) is required, particularly in the case of risk factors including renal impairment, pre-existing cardiovascular disease and diabetes in these patients.
Evaluation of treatment efficacy:
The cessation of ongoing epidermal detachment and the onset of re-epithelialization are good clinical parameters for evaluating treatment efficacy, but survival remains the most valid clinical outcome measure. The contribution of IVIg to the healing process is difficult to assess.
6. Long-term therapy: Not applicable.
Other possible treatment indications:
IVIg has been described as an effective treatment method in numerous clinical conditions in dermatology. Some of the more frequent entities will be mentioned here, although a conclusive assessment is not possible at present. 
Summary:
The treatment recommendations presented for the use of IVIg in dermatology highlight the importance of IVIg therapy in numerous defined dermatological autoimmune diseases and in toxic epidermal necrolysis. The value of IVIg therapy in diseases which are otherwise refractory to treatment is undisputed. Clear treatment recommendations can therefore be given for the diseases described above. Because the exact mechanisms of action of IVIg in vivo are still unclear in these conditions, further efforts should be made to launch randomized controlled trials despite the rarity of some of the disorders described. The current guideline recommendations are intended to create a basis for future randomized controlled trials. The implementation of this EU guideline in general practice means that the use of IVIg in dermatology will be optimized throughout Europe.
Methodology / Additional information
The European guidelines presented here were prepared by a panel of experts nominated by the EDF and the EADV in order to present the indications for treatment currently considered as effective and to summarize the evidence base for the use of IVIg.
These guidelines are intended to support informed therapeutic decision making on the use of IVIg for dermatologists. External reviewing was done according to EDF SOP for guidelines development over a period of 4 weeks, including the members of the EDF guidelines commission, the EADV Board and the UEMS (Union Européenne des Médecins Spécialistes). During the review period, the draft was piloted within the departments of the participating experts. Comments and necessary changes coming from the external review were being discussed among the authors.
European guidelines are subject to national or regional adaptation with consideration of local circumstances (regulatory approval and availability of treatments, health care provider and insurance systems). Thus, the national medical societies associated to the EDF will be responsible for the adaption and implementation of the guidelines on a national level.
Due to the increasing amount of publications, guidelines need to be continually updated to reflect the recent state of evidence. After December 31 st , 2019 these guidelines will expire.
Should important changes occur in the meantime, such as new available interventions, new important evidence or withdrawal of drug licensing, the information contained in the guidelines will be outdated earlier. In these cases, an update issue of the guidelines is needed earlier. The EDF in cooperation with the current guidelines coordinator (Enk) will be responsible to initiate an update. Table 1 Indications for the use of IVIg Table 2 Recommended dosage regimens Dosage: total 2 g/kg body weight *, applied over a period of 2-5 days
Treatment interval:
initially every 4 weeks / after 6 months gradually increase to 6-week intervals **
Long-term therapy:
In individual cases *3 g/kg body weight in toxic epidermal necrolysis** Only 1 cycle in Kawasaki´s disease and toxic epidermal necrolysis
